GlassScriptPhysician profile
Victor Hong
NPI 1134155401
$12,287.97
in general payments reported to CMS, 2019-2025
34 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $587 · 2021: $2,698 · 2022: $2,114 · 2023: $1,733 · 2024: $1,975 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,878.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,034.24 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $1,742.98 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $1,515.37 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $731.90 | 2021-2025 | Azstarys |
| Alkermes, INC. | $613.96 | 2019-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $572.49 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $572.22 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $534.63 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $417.22 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $407.75 | 2019-2025 | Ingrezza |
| Eisai INC. | $407.40 | 2020-2022 | |
| Lundbeck LLC | $314.38 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $277.88 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $276.50 | 2020-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $194.17 | 2019-2024 | Jornay Pm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $192.27 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $175.87 | 2025 | Cobenfy, Coumadin |
| Avanir Pharmaceuticals, INC. | $165.69 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $162.93 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $153.62 | 2023-2025 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $133.12 | 2019-2025 | Adzenys Xr-Odt |
| Allergan, INC. | $128.22 | 2019-2020 | |
| Axsome Therapeutics, INC. | $122.31 | 2023-2025 | Auvelity |
| Tris Pharma INC | $121.20 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Bausch Health US, LLC | $53.01 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $45.58 | 2019 | |
| Merck Sharp & Dohme LLC | $43.32 | 2022-2023 | Belsomra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $39.43 | 2025 | Rexulti |
| Almatica Pharma LLC | $36.87 | 2024-2025 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $36.02 | 2019-2021 | |
| Neuronetics, INC. | $25.71 | 2019 | |
| Shire North American Group INC | $15.71 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $12.22 | 2019 | |
| Adlon Therapeutics L.P. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.